The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study
HER2-positive MIBC has relatively good prognosis, and age ⩽40 years might be a poor prognostic factor. CT or targeted therapy seemed to bring little benefit for MIBC. Further prospective studies are needed to assess potential benefits of management for MIBC patients under the age of 40 years in the future.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Zitong Feng (ORCID: https://orcid.org/0000-0001-5871-9059)
- Jiayi Huang (ORCID: https://orcid.org/0009-0003-4353-2576)
- Changyuan Guo
- Tao Sun (ORCID: https://orcid.org/0000-0001-7255-9039)
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Binghe Xu (ORCID: https://orcid.org/0000-0002-6863-5024)
- Xiaoying Sun (ORCID: https://orcid.org/0000-0001-7503-3921)
- Dan Lv (ORCID: https://orcid.org/0009-0002-7529-6937)
- Ying Fan
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
- Liaoning Cancer Hospital & Institute (CN)
- China Medical University (CN)
Publication Details
- Journal
- Therapeutic Advances in Medical Oncology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/17588359251345716
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00